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Background
The clinical behavior of follicular lymphoma is largely determined by properties of the
non-malignant tumor microenvironment. The precise nature of the cell populations is still
unclear and published data on their prognostic significance are highly conflicting. This
may be partly due to heterogeneous composition and treatments.
Design and Methods
Pre-treatment biopsy samples of patients with follicular lymphoma treated in an
EORTC/BNLI trial comparing fludarabine to cyclophosphamide, vincristine and pred-
nisone (CVP) chemotherapy could be retrieved for 61 patients in five European countries.
Immunohistochemical investigations were performed to evaluate tumor cell characteris-
tics, T-cell subsets, follicular dendritic cells and macrophages and associations with clini-
cal outcome were studied.
Results
Some markers showed a homogeneous prognostic impact, while others had a different
and sometimes opposite effect in the treatment arms. CD69 expression on tumor cells was
a poor prognostic sign and an interfollicular infiltrate of FoxP3-positive T cells was a good
prognostic sign irrespective of the treatment arm. It is suggestive that a dense infiltrate of
FoxP3-positive T cells, a dense and interfollicular infiltrate of CD68-positive macrophages
and complete follicular dendritic meshworks were associated with a favorable time to pro-
gression in CVP-treated patients, while being a poor prognostic sign in fludarabine-treat-
ed patients. 
Conclusions
Our results suggest that characteristic properties of the microenvironment in follicular
lymphoma determines the responses to essentially different chemotherapeutic approach-
es. These data may provide an explanation for the highly conflicting results on immuno-
histochemical markers and the prognostic role of the microenvironment in follicular lym-
phoma reported thus far and lay the basis for the development of predictive assays to tai-
lor treatment in patients with follicular lymphoma.
Key words: follicular lymphoma, microenvironment, prognostic factors, immunohisto-
chemistry.
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Introduction
Follicular lymphoma (FL) is an indolent disease charac-
terized by frequent relapses that generally respond well
to various chemotherapeutic approaches. Until the intro-
duction of chemo-immunotherapy, no single treatment
regimen had been shown to provide a significantly supe-
rior overall survival, despite improvements in progres-
sion-free survival.1 The introduction of rituximab may,
however, be changing this situation for the first time.2,3
The overall survival of FL patients varies greatly, but
approximately 20% of the patients die early in the course
of the disease. Up to now, clinical prognostic indices,
such as the International Prognostic Index and the dis-
ease-specific Follicular Lymphoma International
Prognostic Index (FLIPI) have been the only practical indi-
cators of the clinical course.4
From a biological point of view, the clinical behavior of
FL is determined principally by the tumor microenviron-
ment rather than by inherent properties of the tumor cells
themselves.5-7 Specific T-cell and accessory cell popula-
tions, including macrophages and follicular dendritic cells,
have been reported to have an influence on overall and/or
progression-free survival, either as a poor or a good prog-
nostic parameter.6,8-16 The results of various studies are,
however, very contradictory, with specific cell popula-
tions being correlated with a poor prognosis in some
series, but with a good prognosis or without any signifi-
cant impact in others. In general, these studies were well-
performed and although some of the variability in results
might be explained by technical scoring variations,17 the
explanation probably lies more in the diversity of the clin-
ical characteristics of the patients and their treatments
(Table 1). Specifically, there is evidence suggesting that
very aggressive treatment, as in the series reported by
Farinha et al., has a different impact compared to that of
the standard, more indolent treatment in the UK and the
Netherlands, such as the standard CHOP-like treatment
commontly used in many other countries.6,8,9 Rituximab
has been suggested to influence the prognostic impact of
potential prognostic markers in FL as it does in diffuse
large B-cell lymphoma.13,18-21 Moreover, due to its specific
targeting of T cells, fludarabine may have a different
impact on the FL microenvironment. The prognostic
value of different T-cell populations may, therefore, be
different in patients treated with fludarabine. These
aspects can only be studied appropriately in the setting of
randomized clinical trials. 
To gain insight into the possible influence of treatment
Table 1. Comparison of published data and results from this study on clinico-pathological correlations for T-cell populations, macrophages and fol-
licular dendritic cells. 
Statistically significant association with good, respectively poor prognosis. Borderline significant or trend to good, respectively poor prognosis, in bold:
no association with prognosis.n.d.: not done,n.a.: not available, e-o-s: end-of-spectrum analysis,PFS: progression-free survival,OS: overall survival,DSS: disease-specif-
ic survival.CHOP: cyclophosphamide,doxorubicin, vincristine,prednisone,R: rituximab,MCP: mitoxantrone, chlorambucil, prednisone,BP-VACOP: bleomycin, cisplatin, etopo-
side,doxirubicin, cyclophosphamide,vincristine,prednisone,RT: radiotherapy. apersonal communication,performed on the same series (R.Gascoyne), bspecifically stated as
perifollicular, cPFS only,not OS, dbased on flow data.
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on the predictive value of different cell populations in the
microenvironment, we evaluated these aspects in
patients who were treated in a phase III, prospective, ran-
domized controlled trial comparing fludarabine versus
cyclophosphamide, vincristine and prednisone (CVP) in
previously untreated patients with FL.22
Design and Methods
Patients
Between 1993 and 1997, a phase III, prospective, ran-
domized controlled trial was conducted to compare the
safety and efficacy of eight cycles of fludarabine phos-
phate versus conventional CVP in previously untreated
patients with malignant low-grade non Hodgkin’s lym-
phoma. The study was conducted in nine countries and
60 study centers of the European Organization for
Research and Treatment of Cancer Lymphoma Group
(EORTC LG, n=276 patients) or of the British National
Lymphoma Investigation (BNLI, n=105 patients).
Patients with various classes of indolent B-cell non-
Hodgkin’s lymphoma were treated in this study;
approximately 60% of the  patients had grade 1 or 2 FL. 
Representative formalin-fixed paraffin-embedded
biopsy samples could be retrieved retrospectively for 61
FL patients from 17 centers in the Netherlands, Belgium,
Switzerland, France and Portugal. Of these, 31 samples
came from patients treated with fludarabine and 30
from patients in the CVP arm of the study. For local reg-
ulatory reasons BNLI centers were not able to partici-
pate in the translational research project.
Immunohistochemistry
Tissue micro-arrays were constructed at the National
Cancer Institute in Amsterdam from the tumor blocks
according to standard method, using triplicate 1 mm
cores from pretreatment representative lymph node
biopsy samples for each patient. The sections were
stained with antibodies to evaluate tumor cell charac-
teristics, T-cell subsets, follicular dendritic cells and
macrophages as listed in Table 2. The amount and the
patterns of infiltration of tumor cells, T cells, T-cell sub-
sets and macrophages, and the integrity of follicular
dendritic cell meshworks were semi-quantitatively
assessed by two collaborators in a consensus mode (DJ,
SH). The sampling of three cores per case was consid-
ered to provide a representative sample of the whole
lymph node and results were averaged for a final score. 
Scoring was performed as described previously.6 In
brief, for CD20 the pattern of interfollicular tumor cell
distribution was scored. MIB1 staining was assessed
semi-quantitatively as a proportion of the total number
of tumor cells. CD3 was used as a reference for the total
number of T cells for subpopulations of CD4, CD8 and
FoxP3-positive cells. Staining for these cells was
assessed semi-quantitatively into three classes (0-5%, 5-
10%, >10%). Moreover, the CD4-positive T-cell distri-
bution pattern was assessed as predominantly intrafol-
licular, predominantly interfollicular or diffuse.
Likewise the pattern of FoxP3-positive cells was record-
ed as predominantly intrafollicular, predominantly
interfollicular or diffuse. CD69, a marker of T-cell acti-
vation, was scored relative to the total number of T cells
(absent or sporadically positive cells versus uniformly
weakly or strongly positive). CD69 was considered pos-
itive on tumor cells when more than 75% of the cells
were stained. A distinction between T-cell staining and
tumor cell staining could be made on the basis of mor-
phology and infiltration patterns. CD21 and CD23
markers of follicular dendritic cell meshworks, were
scored in a four-tiered classification (absent, minority of
the neoplastic follicles with disrupted meshworks,
majority of neoplastic follicles with well-developed
meshworks, uniformly well-developed meshworks).
CD68-positive macrophages were counted as absolute
cell numbers per three representative follicular high
power fields (at magnification 600x). Quantification
was performed in duplicate. The spatial distribution of
CD68-positive macrophages was recorded as predomi-
nantly intrafollicular, predominantly interfollicular or
diffuse.
The T-cell markers and macrophage marker (CD3,
CD4, CD8 and FoxP3) were scored in three categories,
follicular dendritic cell patterns (CD21 and CD23) and
proliferation (MIB-1) were scored in four classes.
Because of the limited sample size, these parameters
were analyzed as binary variables and classes were col-
lapsed according to their distribution to result in bal-
anced groups for T cells and macrophages or to biolog-
ically meaningful classes for follicular dendritic cell pat-
terns and proliferation. Specifically, proliferation (MIB-
1) was assessed with a 10% cut-off level, follicular den-
dritic cell patterns were assessed as nearly
complete/uniform versus absent/mostly incomplete,
FoxP3-positive T-cells were analyzed using a cut-off of
5% and CD4 and CD8 using a cut-off of 10%. CD68-
positive macrophages were analyzed using a cut-off
level matching that described by other researchers
(15/high power field).8,13,15
Results were analyzed at the EORTC Data Center
and correlated with clinical data (MG).
Statistical analysis
Response to therapy (complete and partial response)
and time to progression were chosen as the primary
Table 2. Antibodies used in this study.
Antibody Clone Source
Ki-67 MIB1 DAKO
CD20 L26 DAKO
CD3 CD3 DAKO
CD4 4B12 Novacastra
CD8 C8/144B DAKO
FoxP3 236A/E7 AbCam
CD21 1F8 DAKO
CD23 1B12 Novacastra
CD68 KP1 DAKO
CD69 CH11 LabVision
DAKO (Glostrup,Denmark); Novacastra (Newcastle upon Tyne,United Kingdom)
Zymed (Invitrogen,Breda, the Netherlands); Becton Dickinson (Franklin Lakes,NJ,
USA); Abcam (Cambridge,United Kingdom); LabVision (Fremont,CA,USA).
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end-points of this analysis since these data were fully
and reliably available in contrast to information on sub-
sequent treatment protocols that were expected to be
highly variable and would, therefore, have precluded
meaningful interpretations of overall survival. 
Time to progression was defined as time from ran-
domization to disease progression; patients who were
still progression-free at the last documented follow-up,
and patients who died without any sign of progression
were censored on the date of death or last follow-up.
Because of the limited sample size, all immunohisto-
chemical parameters were analyzed as binary variables.
For each end-point, the prognostic value of all parame-
ters was first investigated in univariate prognostic mod-
els; multivariate models were subsequently used to test
whether the statistical significance was independent of
clinical prognostic factors.
Predictive factors (factors predicting the randomized
treatment effect) were identified using multivariate
models including treatment, the tested covariate, and an
interaction factor.
Logistic models and Wald’s χ2 tests were used for all
analyses of response, Cox models and Wald χ2 tests
were used for all analyses of time to progression, and
the Kaplan-Meier method was used to estimate time to
progression.
Results
Patients’ characteristics and disease features
The baseline characteristics of the patients included in
this study are listed in Table 3. The median follow-up at
the time of the current analysis had reached 9.1 years
(actuarial estimate). Ten patients were still alive and
progression-free at the last documented follow-up, in
2006 (3 patients), 2005 (1 patient), 2004 (1 patient), 2003
(1 patient) or before the final analysis report in 2003 (4
patients). The median overall survival was 10.6 years;
the median time to progression, the principle end-point
for this study, was 17 months. In a univariate analysis,
FLIPI score itself had a borderline prognostic value
(p=0.07, HR 1.41, CI 0.97-2.04); lactate dehydrogenase
(LDH) concentration, as a single component, had a sig-
nificant prognostic value (p=0.0086, HR 2.17 CI 1.22-
3.86). In a multivariate model, only LDH level retained
a prognostic significance for time to progression. 
Immunohistochemical analyses and clinical
correlations
Immunohistochemical prognostic markers for time 
to progression for all patients
In a Cox univariate analysis for all patients (Table 4),
it was seen that CD69, an activation marker on tumor
cells, had a statistically significant (p=0.0195) unfavor-
able impact. Other tumor cell-related factors, including
proliferation as measured with MIB-1, did not have sta-
tistically significant effects. The presence of an interfol-
licular component of FoxP3-positive T cells, irrespective
of a concomitant intrafollicular component (interfollicu-
lar and diffuse patterns), correlated significantly
(p=0.0033) with a better prognosis (in terms of time to
progression) (Figure 1A). The amount of FoxP3-positive
cells was not relevant in this respect.
In a multivariate Cox model including the statistically
significant clinical prognostic factors (FLIPI score and
LDH level) and immunohistochemical parameters,
FoxP3 spatial distribution retained its significance
(p=0.0025 when adjusted for FLIPI score, p=0.0084
when adjusted for LDH level).
Immunohistochemical prognostic markers for time 
to progression per treatment arm
When we separately analyzed prognostic factors in
the randomized treatment arms, we observed that the
impact of each factor (measured by its hazard ratio)
sometimes differed substantially between the two
arms: for some factors, the impact was favorable
(HR<1) in one arm and unfavorable (HR>1) in the other
arm (Table 4). This suggests that some of the factors,
even if they do not show a significant prognostic value
in the overall population, may have a predictive value
for the treatment effects, i.e. affect the relative efficacy
of the investigational treatment (fludarabine) when
compared with the control arm (CVP). The predictive
value of all factors was formally investigated by using a
Table 3. Clinical characteristics of fludarabine- and cyclophos-
phamide, vincristine and prednisone-treated patients. 
Fludarabine CVP Total
(n=31) (n=30) (n=61)
N (%) N (%) N (%)
FLIPI
Low 8 (25.8) 8 (26.7) 16 (26.2) 
Intermediate 13 (41.9) 14 (46.7) 27 (44.3) 
High 10 (32.3) 8 (26.7) 18 (29.5) 
Age group
< 40 years 2 (6.5) 5 (16.7) 7 (11.5) 
40-50 years 11 (35.5) 10 (33.3) 21 (34.4) 
50-60 years 9 (29.0) 11 (36.7) 20 (32.8) 
60-70 years 5 (16.1) 4 (13.3) 9 (14.8) 
≥ 70 years 4 (12.9) 0 (0.0) 4 (6.6) 
Ann Arbor stage
III A 8 (25.8) 5 (16.7) 13 (21.3) 
IIIB 2 (6.5) 1 (3.3) 3 (4.9) 
IIIsB 1 (3.2) 0 (0.0) 1 (1.6) 
IV A 15 (48.4) 19 (63.3) 34 (55.7) 
IV B 5 (16.1) 5 (16.7) 10 (16.4) 
Number of involved nodal areas
1 0 (0.0) 4 (13.3) 4 (6.6) 
2 7 (22.6) 5 (16.7) 12 (19.7) 
3 6 (19.4) 2 (6.7) 8 (13.1) 
4 10 (32.3) 8 (26.7) 18 (29.5) 
5 4 (12.9) 8 (26.7) 12 (19.7) 
6 or more 4 (12.9) 3 (10.0) 7 (11.5) 
Baseline hemoglobin
≥120 g/L 25 (80.6) 26 (86.7) 51 (83.6) 
<120 g/L 6 (19.4) 4 (13.3) 10 (16.4) 
Baseline LDH
≤250 IU 16 (51.6) 18 (60.0) 34 (55.7) 
>250 IU 15 (48.4) 12 (40.0) 27 (44.3) 
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multivariate Cox-model and interaction test.
CD23 score was identified as a statistically signifi-
cant predictive factor (p=0.036, interaction test), while
the CD21 score had a borderline predictive value
(p=0.062, interaction test) (Figure 1B). For both factors,
the presence of meshworks was associated with a
longer time to progression in the CVP arm, while
absence of this factor was associated with a longer time
to progression in the fludarabine arm.
Other such interactions were suggested by the data,
but without having a statistically significant predictive
value. The presence of a follicular component of CD3
was a relatively poor prognostic sign for patients
receiving fludarabine treatment, but of no impact for
those treated with CVP. Very interestingly, the density
of the FoxP3-positive T-cell infiltrate and CD68-posi-
tive macrophage content had opposite effects in the
two treatment arms: FoxP3-positive T-cell infiltrates
containing more than 5% of T cells were of adverse
prognostic impact in the fludarabine treatment arm but
of good prognostic impact among patients treated with
CVP. The prognostic significance of CD68-positive
macrophages was similar but the reverse. 
Response to therapy
The overall study results demonstrated an advantage
from fludarabine in terms of response to therapy;18 in
the patients included in the current analysis, we
observed the same trend. In a univariate analysis study-
ing the response to therapy in all patients defined as
reaching complete or partial response, none of the fac-
tors showed a statistically significant correlation. Levels
of borderline significance were reached for the amount
of CD8 (p=0.068) and HLA-DR (p=0.077). 
We next investigated the predictive value for the
treatment effects, i.e. the relative efficacy of fludara-
bine treatment as compared to CVP treatment (Table
5). Predictive models were constructed for all immuno-
histochemical parameters. CD21 score was identified
as a predictive factor (p=0.034). In patients with absent
or sporadic follicular dendritic cell meshworks, the
observed response rate was 95% (18/19) for fludara-
bine vs. 54% (7/13) for CVP (p=0.01, Fisher’s exact test).
In contrast, among patients with mostly well-formed
meshworks, the response rate was 67% (6/9) for flu-
darabine vs. 75% (12/16) for CVP (p=0.82, Fisher’s
exact test). The data also suggested that an interfollicu-
lar component of macrophages, irrespective of the pres-
ence of an intrafollicular component (interfollicular
only and/or diffuse), was related to a lesser chance of
reaching response after fludarabine treatment, but did
not influence the response rate after CVP treatment
(p=0.08 with an odds ratio of 0.111 for fludarabine, p=1
for CVP), although this was not statistically significant.
Discussion
Various gene-expression and immunohistochemical
studies have provided strong evidence of the impor-
| 74 | haematologica | 2009; 94(1)
Figure 1. (A) Survival curves
(time to progression) based on
the presence of an interfollicu-
lar component of FoxP3-posi-
tive T cells. (B) Survival curves
per treatment arm (time to
progression) based on the
presence of (near) complete
CD23 and CD 21 positive follic-
ular dendritic cell meshworks.
A B Time to progressionTime to progression
Overall Logrank test: p=0.001
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foxp3_int
No interfollicular component
interfollicular component
FLU/CD23- CVP/CD23- FLU/CD23+ CVP/CD23+ FLU/CD21- CVP/CD21- FLU/CD21+ CVP/CD21+
(years)(years) (years)
Time to progression
CD21 Treatment N O HR p Median (CI) % at 5 years (CI)
Absent/ CVP 13 12 1.00 1.59 (0.73, 4.45) 0.00(,)
Sporadic Fludarabine 21 14 0.63 (0.29, 1.36) 1.56 (1.33, N) 30.00 (12.25, 50.14)
Sporadic Fludarabine 12 6 0.44 (0.16, 1.18) 2.18 (1.56, N) 45.45 (16.66, 70.69)
Present/ CVP 16 13 1.00 2.14 (1.36, 5.39) 31.25 (11.39, 53.65)
Present/ CVP 17 13 1.00 1.91 (1.17, 5.39) 28.24 (9.62, 50.50)
Uniform Fludarabine 19 16 1.58 (0.75, 3.32) 1.33 (0.96, 2.17) 11.40 (1.92, 30.35)
Uniform Fludarabine 10 8 1.99 (0.78, 5.06) 1.21 (0.68, 2.17) 12.00 (0.66, 40.79)
Absent/ CVP 12 12 1.00 1.59 (1.02, 4.45) 8.33 (0.51, 31.11)
CD23
0.2323
0.1436
0.0943
0.2277
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tance of the microenvironment in the clinical behavior
of FL.5-7 The precise nature of the relevant cell popula-
tions is still unclear, and published data on the prognos-
tic significance of cell populations, including T-cell sub-
sets, macrophages and follicular dendritic cells, are con-
flicting.6,8-16 The analysis of pre-treatment samples from
FL patients treated in the EORTC/BNLI 20921 trial
enabled us to study the impact of essentially different
chemotherapeutic approaches: CVP is principally
directed towards the tumor cells, whereas fludarabine is
directed towards both tumor cells and the microenvi-
ronment, especially the T-cell populations. In this clini-
cal trial overall response rates were significantly better
in the fludarabine arm than in the CVP arm, but there
were no statistically significant differences in time to
progression, time to treatment failure, and overall sur-
vival between treatment groups.18 This was true for the
whole cohort of patients as well as for the subgroup
Table 4. Immunohistochemical prognostic factors for time to progression.
All patients Fludarabine Cyclophosphamide, vincristine
and prednisone
Variable p HR p HR p HR
CD3 Follicular component 0.3830 1.353 0.0922 2.968 0.9470 0.971
Interfollicular component 0.5081 0.617 0.2158 0.261 0.9202 0.902
Amount 0.5053 1.297 0.3576 1.598 0.7110 0.792
CD4 Follicular component 0.6725 1.153 0.7827 1.193 0.4630 1395
Interfollicular component 0.1259 0.392 0.9991 0.000 0.3781 0.507
Amount 0.3485 0.753 0.8201 0.907 0.2732 0.619
CD8 Follicular component 0.9552 0.976 0.5474 1.400 0.5524 0.643
Amount 0.4378 0.791 0.8767 0.935 0.4293 0.719
CD21 Score 0.9877 0.995 0.2219 1.731 0.1291 0.527
CD23 Score 0.4142 1.280 0.0469 2.620 0.3164 0.663
CD68 Follicular component 0.6607 1.147 0.6167 1.271 0.9499 1026
Interfollicular component 0.2516 0.710 0.0794 0.468 0.9058 1052
Amount 0.4807 1.227 0.1672 1.814 0.5671 0.795
CD69 T-cells 0.1300 0.633 0.7277 0.859 0.0783 0.479
Tumor cells 0.0195 2.735 0.0797 2.721 0.1381 2640
FOX-P3 Follicular component 0.9368 1.027 0.5855 1.299 0.7655 0.874
Interfollicular component 0.0033 0.189 0.0315 0.182 0.0580 0.217
Amount 0.7920 0.924 0.3379 1.512 0.1761 0.554
HLADR Score 0.1226 0.479 0.0552 0.109 0.2741 0.545
KI67 Score 0.3190 1.340 0.3524 1.488 0.5955 1241
Table 5. Immunohistochemical prognostic factors for response to treatment.
All patients Fludarabine Cyclophosphamide, vincristine
and prednisone
Variable p OR p OR p OR
CD3 Follicular component 0.3371 2.000 0.3432 3.667 0.9008 1.114
Interfollicular component 0.9757 >> 0.9800 >> 0.9801 >>
Amount 0.4571 1.875 0.9612 >> 0.5247 0.500
CD4 Follicular component 0.8544 1.143 0.7373 1.556 0.7527 0.750
Interfollicular component 0.9757 >> − − 0.9734 >>
Amount 0.5113 1.557 0.4471 2.538 0.9304 1.077
CD8 Follicular component 10.000 1.000 0.6894 1.667 0.9275 0.889
Interfollicular component 0.9829 >> 0.9800 >> − −
Amount 0.0680 0.309 0.1905 0.200 0.1785 0.333
CD21 Complete 0.5947 1389 0.0781 9000 0.2388 0.389
CD23 Complete 0.8259 0.872 0.5344 2143 0.4958 0.583
CD68 Follicular component 0.9114 0.931 0.7425 1500 0.7889 0.808
Interfollicular component 0.2768 0.500 0.0781 0.111 1 1000
Amount 0.6419 1333 0.2421 4199 0.6032 0.667
CD69 T-cells 10000 1000 0.6325 1800 0.7246 0.750
Tumor cells 0.7700 0.712 0.9717 <0.001 0.8881 0.833
FOX-P3 Follicular component 0.7308 0.775 1 1000 0.6106 0.619
Interfollicular component 0.6724 0.585 0.9800 >> 0.5829 0.444
Amount 0.4482 1620 1 1000 0.2316 2708
HLADR Positive 0.0772 0.179 0.9746 <0.001 0.4885 0.471
KI67 > 5% 0.3221 1852 0.8771 1182 0.2388 2571
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In the series of samples from FL patients in the
EORTC 20921 trial that could be studied using
immunohistochemisty, some markers showed an over-
all prognostic impact, while others had a very different
and sometimes opposite effect in the different treat-
ment arms. It should be noted, however, that due to the
small size of this series, the effect of most immunohis-
tochemical parameters failed to reach full statistical sig-
nificance and the results should, therefore, be interpret-
ed with great caution. LDH level was a significant prog-
nostic factor as also reflected in borderline significance
for the FLIPI score. CD69 expression on tumor cells
was related with a poor outcome in both treatment
arms. A dense infiltrate of CD4-positive T cells, espe-
cially when located interfollicularly, was a good prog-
nostic sign irrespective of treatment arm. This is in line
with previous reports.9,10
In view of the highly conflicting results in the litera-
ture, the differential effects of FoxP3-positive T cells
and CD68-positive macrophages on time to progres-
sion found in this series are of most interest. In the
patients who were treated with CVP, a dense infiltrate
of FoxP3-positive T cells, especially with an interfollic-
ular component, was associated with a better survival.
In the patients treated with fludarabine, however, the
dense infiltrate was associated with a shorter time to
progression. We found a similar treatment-related dif-
ferential effect of CD68 positive macrophages: a dense
infiltrate was a good prognostic sign in CVP-treated
patients and a poor prognostic sign in those treated
with fludarabine. The presence of complete or nearly
complete follicular dendritic cell meshworks expressing
CD23 and to a lesser extent CD21 was associated with
a longer time to progression in CVP-treated patients,
while being a poor prognostic sign in fludarabine-treat-
ed patients. 
How do these findings relate to results from other
published series? In the present study, the poor prog-
nostic impact of a dense infiltrate of CD68-positive
macrophages in fludarabine-treated patients was very
similar to that of the impact in patients treated with the
intensified BP-VACOP, as reported by Farinha et al.8
The prognostic direction in CVP-treated patients was,
however, more in line with that of other studies,
although most authors did not find a prognostic signif-
icance for this marker9,10 (Table 1). The findings for
FoxP3-positive T cells are also highly conflicting with
the series of BP-VACOP-treated patients showing
opposite results as compared to those of all other
series.8-10 Again, we found that the prognostic trend in
fludarabine-treated patients paralleled that in the BP-
VACOP-treated patients, while in the CVP-treated
patients the impact of both the density of the FoxP3-
positive T cells and their spatial distribution reflected
that in other series of patients treated less intensively. It
should be noted, however, that the treatments in these
series were highly varied with mostly indolent type reg-
imens in the series reported by Lee and co-workers, but
also including CHOP in the two other series.
Nevertheless, although these comparisons should all be
regarded with caution in view of the highly heteroge-
neous treatments in most reported series, the different
clinical risk distributions, the variations in scoring crite-
ria and the small size of the present EORTC 20921
series, these data do suggest that the microenviron-
ment plays a different role in FL in the context of spe-
cific treatment regimens. This notion is further sup-
ported by the different prognostic impact that was
found for CD68-positive macrophage infiltrates and
mast cells in FL patients treated with CHOP with and
without rituximab.13,16,18
Taken together, based on previous studies by us and
others and on the present data, it can be hypothesized
that there may be two different classes of FL response:
FL that contain a complete, dense microenvironment
with many macrophages, FoxP3-positive T cells and
CD23-positive follicular dendritic cells have a more
favorable outcome after CVP treatment, while FL with
these same microenvironmental characteristics are
associated with a poor outcome after treatments that
are also directed towards the microenvironment (flu-
darabine and BP-VACOP).6,7,27 It has been shown that
fludarabine has a rather specific effect on FoxP3-posi-
tive regulatory T cells in patients with B-cell chronic
lymphocytic leukemia, in that both the frequency and
the inhibitory functions of these cells are reduced after
treatment.23-25 Very likely, interference with the tumor
microenvironment may result in different responses
depending on the specific role of the microenvironment
in a specific class of FL. Similar effects of cyclophos-
phamide have been shown on regulatory T cells too.26
In conclusion, although this was a relatively small
series, the patients were uniformly treated within a
clinical trial. The data provide an explanation for the
highly conflicting results on immunohistochemical
markers and the prognostic role of the microenviron-
ment in FL as reported thus far and lay the basis for the
development of predictive assays that may help to tai-
lor treatment in patients with FL. Moreover, this study
highlights the importance of translational studies as an
integral part of clinical trials in lymphoma. Combined
efforts by different trial organizations will be necessary
to provide sufficient data to study this issue further.27
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